- London
- Hybrid
- Director
Leads end-to-end translational strategy for neurodegenerative and neuromuscular programs, bridging preclinical research to Phase 1–2 clinical development. Accountable for biomarker strategy, clinical endpoint selection and early-phase trial design, and serves as the Translational Medicine representative within global cross-functional project and clinical trial teams.